Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q92599
UPID:
SEPT8_HUMAN
Alternative names:
-
Alternative UPACC:
Q92599; A6NC65; A6NKP6; F6W7K9; Q8IX36; Q8IX37; Q9BVB3
Background:
Septin-8, encoded by the gene with accession number Q92599, is a filament-forming cytoskeletal GTPase. It is implicated in various cellular processes, including platelet secretion and the formation of SNARE complexes in synaptic vesicles, essential for neurotransmitter release. Additionally, Septin-8 plays a crucial role in stabilizing BACE1 protein levels, influencing the sorting and accumulation of BACE1 in recycling or endosomal compartments. This activity is vital for the beta-amyloidogenic processing of APP, a precursor molecule to amyloid beta, which is central to Alzheimer's disease pathology.
Therapeutic significance:
Understanding the role of Septin-8 could open doors to potential therapeutic strategies, particularly in neurodegenerative diseases where synaptic function and amyloid beta processing are disrupted.